🇺🇸 FDA
Patent

US 11931340

Use of sublingual dexmedetomidine for the treatment of agitation

granted A61KA61K31/4174A61K45/06

Quick answer

US patent 11931340 (Use of sublingual dexmedetomidine for the treatment of agitation) held by BioXcel Therapeutics, Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioXcel Therapeutics, Inc.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/4174, A61K45/06, A61K47/10, A61K9/006